Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4436-4455
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4436
BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer
Shu-Liang Li, Pei-Yao Wang, Yang-Pu Jia, Zhao-Xiong Zhang, Hao-Yu He, Peng-Yu Chen, Xin Liu, Bang Liu, Li Lu, Wei-Hua Fu
Shu-Liang Li, Pei-Yao Wang, Yang-Pu Jia, Zhao-Xiong Zhang, Hao-Yu He, Peng-Yu Chen, Xin Liu, Bang Liu, Li Lu, Wei-Hua Fu, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin 300052, China
Shu-Liang Li, Department of Gastrointestinal Surgery, The Second People’s Hospital of Liaocheng, Liaocheng 252600, Shandong Province, China
Shu-Liang Li, Department of Gastrointestinal Surgery, The Second Hospital of Liaocheng, Affiliated to Shandong First Medical University, Liaocheng 252600, Shandong Province, China
Co-first authors: Shu-Liang Li and Pei-Yao Wang.
Author contributions: Li SL and Jia YP contributed to conceptualization, methodology, validation, data curation; Zhang ZX and Liu X contributed to formal analysis and investigation; Liu B and Lu L contributed to supervision, funding acquisition; He HY and Chen PY contributed to writing original draft preparation; Wang PY contributed to writing, review and editing; Fu WH contributed to funding acquisition, review and editing; All authors have read and approve the final manuscript.
Supported by the Tianjin Municipal Education Commission Scientific Research Project, No. 2018KJ055.
Institutional review board statement: The study was reviewed and approved by The Ethical Committee of Tianjin Medical University General Hospital, No. IRB2023-WZ-224.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Tianjin Medical University General Hospital, No. IRB2023-DW-138.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at tjmughgs_fwh@163.com. Participants gave informed oral consent for data sharing.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Hua Fu, MD, PhD, Professor, Surgeon, Teacher, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin Medical University, No. 154 Anshan Road, Tianjin 300052, China. tjmughgs_fwh@163.com
Received: April 23, 2024
Revised: August 13, 2024
Accepted: September 10, 2024
Published online: November 15, 2024
Processing time: 185 Days and 9.1 Hours
Core Tip

Core Tip: Our study discovered that the overexpression of BIRC3 leads to the stimulation of phosphoinositide 3-kinase-Akt phosphorylation and activation. Consequently, this enhances the proliferation of human epidermal growth factor receptor 2-positive tumor cells and inhibits apoptosis, resulting in resistance to trastuzumab.